Deals channel feed – Endpoints News

Deals channel feed

Vertex taps Verve for gene editing pact — buying a chunk of shares — as Sek Kathiresan steers base editing into clinic

3 years ago

Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline

3 years ago

Safety scare cleared and early data in hand, Ultragenyx dishes out $75M to buy rare disease partner

3 years ago

Following Luxturna and slate of eye disease approvals, Roche adds another ophthalmology partner for AAV gene therapies

3 years ago

BlackRock joins Andrew Lo's risk analysis firm to search for odds-on biotech bets in turbulent times

3 years ago

Nestlé puts down $40M, kicks off deal with gut microbiome specialist to fight food allergies

3 years ago

After initial commercial foray, China's CStone mulls sale — report

3 years ago

Bayer sells testosterone treatment to German company for $500M

3 years ago

Ultragenyx sells $500M in royalty interest on rare disease drug to Canadian pension plan

3 years ago

Theravance, Innoviva sell royalty rights on GSK's Trelegy to Royalty Pharma for $1.3B upfront

3 years ago

Illumina loses challenge to block EU antitrust probe into $8B Grail buyout

3 years ago

Novo Nordisk nabs priority review voucher for $110M from Marinus as the biotech preps first drug launch

3 years ago

Sanofi CEO Paul Hudson offloads two portfolios to German pharma company in continued effort to prune products

3 years ago

TherapeuticsMD shares crater as anticipated M&A deal falls through

3 years ago

With eyes on Keytruda patent cliff, Merck takes a $290M swing at prostate cancer

3 years ago

Faheem Hasnain forges a $120M private placement. So what did we learn from that?

3 years ago

How interest in a single cancer drug led to Ipsen's takeover of Epizyme

3 years ago

No surrender: A group of marquee biotech players bets on the $350M PhIII resurrection story of a heavyweight contender

3 years ago

Emergent nets another manufacturing deal, this time for Ridgeback's Ebola treatment

3 years ago

Vertex nabs ViaCyte's rival diabetes stem cell treatment, acquiring the biotech for $320M in cash

3 years ago

Ionis hands off an antisense drug for kidney disease, giving all rights to Roche

3 years ago

La Jolla exits to Innoviva in a deal that caps 33 years marked by misses in lupus, malaria and beta thalassemia

3 years ago

Sinopharm mulls $1B buyout of China-based DNA synthesis company — report

3 years ago

Korean diagnostics biotech goes transpacific, agreeing to shell out $1.5B to take Meridian private

3 years ago

First page Previous page 55 56 575859 60 61 Next page Last page